The View from D.C.: Psychedelic Politics, Blockers and Approvals on the Horizon

Psychedelic Alpha editor Josh Hardman shares what he learned from visiting Washington, D.C. about how people with influence over the psychedelics field see the near-term regulatory outlook. Hardman reports a sense of political and regulatory volatility, plus division within the psychedelics community about what priorities to push. Still, some stakeholders expressed quiet confidence that multiple FDA approvals of psychedelics could be close, with as many as three potential approvals within the next 18 months. The dispatch also highlights the range of perspectives encountered, spanning lawyers and lobbyists, agency staffers, advocacy groups, drug developers, and other well-connected individuals, and frames this mix as a key factor behind both current “blockers” and “approvals” that may be on the horizon.